Bortenat 2 mg injection is an anticancer medicine used in the treatment of multiple myeloma & mantle cell lymphoma in adults. It contains Bortezomib works by interfering with the protein mechanism of the cancerous cell to stop or slow down the cancer cells. Bortenat 2 mg injection targets several factors essential for the survival of cancer cells, such as protein metabolism, bone marrow microenvironment, and cell signalling pathways.
Bortenat 2 mg injection (Bortezomib) is an FDA approved anticancer treatment used for multiple myeloma (a cancer of the bone marrow) & mantle cell lymphoma in adults. It works by preventing or slowing down the growth of cancer cells. It can be prescribed alone or with other anti cancer medicines for the effective cancer treatment.
Approval Timeline:
Bortenat 2 mg injection is used in combination with other anti-cancer therapies for the treatment of multiple myeloma & mantle-cell. It acts on the malignant lymphocytes by destroying the regulatory proteins present in these cells. It leads to the disruption of routine cellular processes in malignant cells and causes cell death. In this way, Bortenat 2 mg injection slows down the growth of the malignant tumor and reduces the chances of survival of the malignant lymphocytes.
Multiple myeloma is a type of cancer involving a subset of plasma cells, a type of white blood cell. In this condition, white blood cells in the bone marrow undergo unregulated proliferation, disrupting the region's normal function. This leads to symptoms like bone damage, anemia, kidney problems, and infections. Bortenat 2 mg injection inhibits the āproteosomeā (a type of molecular waste disposal in eukaryotic cells), which causes a buildup of toxic materials in the cells. This buildup triggers apoptosis, i.e., programmed cell death, in cancer cells, thereby reducing the growth of the cancerous mass.
Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma. It arises from the mantle of lymph nodes, where the B cells proliferate uncontrollably. Typical signs of Mantle cell lymphoma include enlarged lymph nodes, fatigue, fever, weight loss, and weakened immunity.
The dosage of Bortenat 2 mg injection is calculated based on body surface area (BSA) calculated in square meters (mĀ²) instead of body weight, which is used for other medications. Hence, the unit of measurement of Bortenate 2 mg dosage is mg/mĀ².
Recommended dose:
Maximum dose:
Missed dose instructions:
Overdose instructions:
Recommended dose:
Maximum dose:
Missed dose instructions:
Overdose instructions:
You can buy Bortenat 2 mg injection from Lifesaving-meds.com at low price online with free shipping & free sample medicines. Lifesaving-meds.com provide Bortenat 2 mg injection at very less wholesale price for sale from India with low price guarantee, big discounts, free delivery, credit card / debit card, Zellepay, paypal, crypto / Bitcoin payment option & more in the United states of America (USA) ā New York, California, Texas, Florida, Ohio, Oregon, Georgia, Denver, Illinois, Oregon, Pennsylvania, Washington, Wyoming & more; United Kingdom (UK) ā London, Birmingham, Wales, Manchester & more; Europe (EU) ā Moscow (Russia), Paris (France), Spain & more; and Australia (AU) ā Sydney, Melbourne, Brisbane & more. So, buy Bortenat 2 mg injection near you when you are prescribed with this medication or search as Bortenat 2 mg injection for sale near me on google, bing, yahoo, duckducko, AOL & anywhere.
Bortenat 2 mg injection contains 2 mg of the drug Bortezomib, which is an anticancer medication. It is typically used in the treatment of multiple myeloma and mantle cell lymphoma. It belongs to a class of drugs known as proteosome inhibitors. The main mechanism of action of Bortenat 2 mg injection includes interfering with the protein mechanism of the cancerous cell.
In normal cells, damaged or incompletely formed proteins are routinely metabolised by an enzyme complex called the proteosome. This process is essential for excreting waste proteins from the cells and ensuring proper cell functions like cell cycle, signaling pathways, and survival mechanisms. In cancerous cells, especially myeloma and lymphoma cells, there is an excess production of these proteosomes, which removes a large amount of unnecessary proteins to ensure their survival.
The active ingredient of Bortenat 2 mg injection, Bortezomib, specifically targets the 26S proteosome in malignant cells, which is an important protein complex involved in the excretion of many unwanted proteins. As a result, there is a buildup of toxins due to excess misfolded and damaged proteins in the malignant cells. This toxic buildup results in cell stress and disruption of multiple signalling pathways, which triggers a mechanism called programmed cell death (apoptosis).
Bortenat 2 mg also targets another cell survival mechanism in malignant cells known as the NF-ĪŗB signaling pathway. This pathway promotes cell survival, inflammation, and resistance to cell death. By interfering with this pathway, Bortenat 2 mg injection slows the progression of the disease by pushing the cancerous cell towards cell death by decreasing the tumor's ability to grow and withstand treatment.
Bortenat 2 mg acts on the bone marrow environment, thereby inhibiting the growth and proliferation of cancerous cells by disrupting their interaction with the bone marrow. In this way, to halt the growth of malignant lymphocytes and slow down the growth of the tumor, Bortenat 2 mg injection targets some of the survival mechanisms of malignant cells by blocking proteosomes, accumulating toxic proteins, disrupting cervical pathways, and modifying the tumor's microenvironment.
ā > Blood-Related Side Effects of Bortenat 2 mg injection
ā > Nervous System Effects of Bortenat 2 mg injection
ā > Cardiovascular Effects of Bortenat 2 mg injection
ā > Gastrointestinal Effects of Bortenat 2 mg injection
ā > Infection-Related Effects of Bortenat 2 mg injection
ā > Metabolic / Electrolyte Changes
Bortenat 2 mg injection can be administered either subcutaneously or intravenously.
Bortenat 2 mg injection generally does not cause any hair loss; however, there might be some hair thinning.
Yes. Bortenat 2 mg injection can weaken the immune system as it can affect the white blood cells.
Bortenat 2 mg injection is used in the treatment of multiple myeloma and mantle cell lymphoma.
No. Bortenat 2 mg injection must not be administered to pregnant women.
